Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on March 9, 2009

Hypertension. 2009
Published online before print March 9, 2009, doi: 10.1161/HYPERTENSIONAHA.108.118919
A more recent version of this article appeared on April 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
53/4/682    most recent
HYPERTENSIONAHA.108.118919v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Linthout, S.
Right arrow Articles by Tschöpe, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Linthout, S.
Right arrow Articles by Tschöpe, C.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Other diabetes
Right arrow Gene therapy
Right arrowRelated Article

Submitted on July 2, 2008
Revised on July 23, 2008

Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor

Sophie Van Linthout; Frank Spillmann; Mario Lorenz; Marco Meloni; Frank Jacobs; Marina Egorova; Verena Stangl; Bart De Geest; Heinz-Peter Schultheiss; and Carsten Tschöpe*

From the Department of Cardiology and Pneumology (S.V.L., F.S., M.M., M.E., H.-P.S., C.T.), Charité–University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany; Department of Cardiology and Angiology (M.L., V.S.), Charité–University Medicine Berlin, Campus Mitte, Berlin, Germany; and the Center for Molecular and Vascular Biology (F.J., B.D.G.), University of Leuven, Leuven, Belgium.

* To whom correspondence should be addressed. E-mail: carsten.tschoepe{at}charite.de.

Abstract—There is growing evidence that a cross-talk exists between the renin-angiotensin (Ang) system and lipoproteins. We investigated the role of high-density lipoprotein (HDL) on Ang II type 1 receptor (AT1R) regulation and subsequent Ang II–mediated signaling under diabetic conditions. To investigate the effect of HDL on AT1R expression in vivo, apolipoprotein A-I gene transfer was performed 5 days after streptozotocin injection. Six weeks after apolipoprotein A-I gene transfer, the 1.9-fold (P=0.001) increase of HDL cholesterol was associated with a 4.7-fold (P<0.05) reduction in diabetes mellitus–induced aortic AT1R expression. Concomitantly, NAD(P)H oxidase activity, Nox 4, and p22phox mRNA expression were reduced 2.6-fold, 2.0-fold, and 1.5-fold (P<0.05), respectively, whereas endothelial NO synthase dimerization was increased 3.3-fold (P<0.005). Apolipoprotein A-I transfer improved NO bioavailability as indicated by ameliorated acetylcholine-dependent vasodilation in the streptozotocin-Ad.hapoA-I group compared with streptozotocin-induced diabetes mellitus. In vitro, HDL reduced the hyperglycemia-induced upregulation of the AT1R in human aortic endothelial cells. This was associated with a 1.3-fold and 2.2-fold decreases in reactive oxygen species and NAD(P)H oxidase activity, respectively (P<0.05). Finally, HDL reduced the responsiveness to Ang II, as indicated by decreased oxidative stress in the hyperglycemia+HDL+Ang II group compared with the hyperglycemia+Ang II group. In conclusion, vascular-protective effects of HDL include the downregulation of the AT1R.


Key words: high-density lipoprotein • angiotensin AT1 receptor • endothelial function • diabetes mellitus


Related Article:

From Menace to Marvel: High-Density Lipoprotein Prevents Endothelial Nitric Oxide Synthase Uncoupling in Diabetes Mellitus by Angiotensin II Type 1 Receptor Downregulation
Philip Wenzel and Thomas Münzel
Hypertension 2009 53: 587-589. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
HypertensionHome page
P. Wenzel and T. Munzel
From Menace to Marvel: High-Density Lipoprotein Prevents Endothelial Nitric Oxide Synthase Uncoupling in Diabetes Mellitus by Angiotensin II Type 1 Receptor Downregulation
Hypertension, April 1, 2009; 53(4): 587 - 589.
[Full Text] [PDF]